-
Forest Laboratories Inc. et al v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:14-cv-00686
- D. Del.
- Judge: Leonard P. Stark
- Filed: 05/30/2014
- Closed: 07/26/2016
- Latest Docket Entry: 02/21/2018
- PACER
- Docket updated daily
3
Plaintiffs
3
Defendants
1
Accused
Product
6
Patents-in-Suit
789
Days in
Litigation
-
Forest Laboratories Inc. et al v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:14-cv-00686
- D. Del.
- Judge: Leonard P. Stark
- Filed: 05/30/2014
- Closed: 07/26/2016
- Latest Docket Entry: 02/21/2018
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A solid pharmaceutical composition in a unit dosage form for once daily oral administration comprising an extended release formulation of 5 to 40 mg memantine or pharmaceutically acceptable salt thereof, wherein administration of a dose of the
view more
|
Invalid
Entry 241 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of administering memantine to a human subject in need thereof comprising: administering to said subject once daily a sustained release oral dosage form comprising 5 to 40 mg of memantine or a pharmaceutically acceptable salt thereof and a
view more
|
Invalid
Entry 241 |
6 |
A method of reducing the potential for an adverse effect while administering memantine to a human subject in need thereof, comprising: orally administering to the human subject once per day a sustained release oral dosage form comprising 5-40 mg of
view more
|
Invalid
Entry 241 |
10 |
A method of administering memantine to a human subject in need thereof comprising: administering to said subject once daily a sustained release oral dosage form comprising 5 to 40 mg of memantine or a pharmaceutically acceptable salt thereof and a
view more
|
Invalid
Entry 241 |
15 |
A method of reducing the potential for an adverse effect while administering memantine to a human subject in need thereof, comprising: orally administering to the human subject once per day a sustained release oral dosage form comprising 5-40 mg of
view more
|
Invalid
Entry 241 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A solid pharmaceutical composition in a unit dosage form for oral administration comprising an extended release formulation of 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the
view more
|
Invalid
Entry 241 |
9 |
A solid pharmaceutical composition in a unit dosage form for oral administration comprising an extended release formulation of 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the
view more
|
Invalid
Entry 241 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating a patient with a neurological disorder selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain, comprising: administering to said subject once daily a sustained release oral
view more
|
Invalid
Entry 241 |
7 |
A method of treating a patient with a neurological disorder selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain, comprising: administering to said subject once daily a sustained release oral
view more
|
Invalid
Entry 241 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A solid pharmaceutical composition in a unit dosage form for once daily oral administration comprising an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose
view more
|
Invalid
Entry 241 |